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Bronchiolitis obliterans (BO) is a serious complication of allogeneic hematopoietic stem cell transplantation
(HSCT). Lung biopsy is the gold standard for diagnosis. This study describes the course of BO and assesses the
congruity between biopsy-veriﬁed BO and a modiﬁed version of the National Institutes of Health’s consensus
criteria for BO syndrome (BOS) based exclusively on noninvasive measures. We included 44 patients trans-
planted between 2000 and 2010 who underwent lung biopsy for suspected BO. Of those, 23 were diagnosed
with BO and 21 presented other noninfectious pulmonary pathologies, such as cryptogenic organizing
pneumonia, diffuse alveolar damage, interstitial pneumonia, and nonspeciﬁc interstitial ﬁbrosis. Compared
with patients with other noninfectious pulmonary pathologies, BO patients had signiﬁcantly lower values of
forced expiratory volume in 1 second (FEV1), FEV1/forced vital capacity, and maximal mid-expiratory ﬂow
throughout follow-up, but there was no difference in the change in pulmonary function from the time of lung
biopsy. The BO diagnosis was not associated with poorer overall survival. Fifty-two percent of patients with
biopsy-veriﬁed BO and 24% of patients with other noninfectious pulmonary pathology fulﬁlled the BOS
criteria. Pathological BO diagnosis was not superior to BOS criteria in predicting decrease in pulmonary
function beyond the time of biopsy. A lung biopsy may provide a characterization of pathological patterns
that can extend our knowledge on the pathophysiology of HSCT-related lung diseases.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Bronchiolitis obliterans (BO) is a serious complication of
allogeneic hematopoietic stem cell transplantation (HSCT),
clinically deﬁned by airﬂow obstruction and pathologically
characterized by progressive ﬁbrosis and obliteration of the
bronchioles [1,2]. Lung biopsy is the gold standard fordgments on page 537.
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ty for Blood and Marrow Transplantation.diagnosis but is invasive and not widely used in the daily
clinical routine. Instead, multiple diagnostic criteria based on
clinical disease manifestations have been applied, which
may partly explain the variability in the reported incidence
(1.2% to 14.6%) [3-14] and mortality (27% to 90%) [3-5,7,10-
13]. To improve the basis for comparative research without
running the risks associated with lung biopsy, in 2005 the
National Institutes of Health (NIH) published criteria for BO
syndrome (BOS), a clinical equivalent of biopsy-veriﬁed BO
based on pulmonary function (PF) tests and radiology [2].
According to these criteria, BOS is diagnosed in patients
H.H. Uhlving et al. / Biol Blood Marrow Transplant 21 (2015) 531e538532where infectious etiology has been excluded and who
manifest a forced expiratory volume in 1 second (FEV1) <
75% of predicted normal value, FEV1/forced vital capacity
(FVC) ratio < .7, residual volume > 120% of predicted, and
high-resolution computed tomography (HRCT) with signs of
air trapping, bronchiectasis, or peribronchial thickening [2].
However, in a retrospective validation study, only 18% of
patients (4/22) with clinically identiﬁed or biopsy-proven BO
fulﬁlled the criteria [15]. Modiﬁed criteria have therefore
been proposed to improve applicability [15].
Although biopsy-veriﬁed BO is diagnostic for chronic
graft-versus-host disease (cGVHD), fulﬁllment of the BOS
criteria is not by itself diagnostic for cGVHD but requires at
least 1 distinctive extrapulmonary manifestation for the
diagnosis of cGVHD [16,17]. Still, biopsy-based studies are
sparse, and our knowledge on the clinical course of BO and
the level of congruity with BOS is limited. Likewise, it is not
clariﬁed if lung biopsy represents a more sensitive or speciﬁc
prognostic tool than the BOS criteria.
The aims of this study were (1) to describe the course of
biopsy-veriﬁed BO, (2) to assess the congruity between
biopsy-veriﬁed diagnosis and a modiﬁed version of the NIH
BOS criteria, and (3) to compare the prognostic value of these
diagnostic methods in the prediction of pulmonary outcome
and survival.
METHODS
Patient Population
Patients treated with allogeneic HSCT in Denmark between January 1,
2000 and December 31, 2010 who survived beyond 3 months from trans-
plantation were included if a lung biopsy was performed during follow-up
and if this biopsy showed signs of noninfectious pulmonary pathology. In-
fectious pathology was an exclusion criterion. The study was approved by
the Danish National Board of Health (J.nr.3-3013-47/1) and the Danish Data
Protection Agency (J.nr.2007-58-0015).
Data Collection
Clinical data were collected from the Danish reports to the Center for
International Blood and Marrow Transplant Research and patient ﬁles, until
September 2013. The diagnosis of cGVHD was veriﬁed by review of patient
ﬁles to ensure agreement with NIH criteria [2].
Lung Biopsies
Only patients having open (n ¼ 34) or transbronchial (n ¼ 10) biopsies
were included in the study. All biopsies were reviewed by the same expe-
rienced pulmonary pathologist and were classiﬁed as having either BO ac-
cording to NIH’s histopathological criteria [1] or other noninfectious
pulmonary pathologies, such as cryptogenic organizing pneumonia (COP,
previously known as bronchiolitis obliterans organizing pneumonia),
diffuse alveolar damage, interstitial pneumonia (including lymphocytic
interstitial pneumonia), and nonspeciﬁc interstitial ﬁbrosis (peribronchial
or alveolar septal). Microbiological agents in biopsies, bronchoalveolar la-
vages, sputum, and blood samples were evaluated by an experienced
microbiologist and led to exclusion unless considered as contamination (ie,
S. epidermidis) or in case of pathogens not associated with respiratory
symptoms (ie, normal ﬂora of the oropharynx).
HRCT
Chest HRCTs performed before diagnostic biopsies were described
independently by 2 senior radiologists whowere blinded to the pathological
diagnosis. The ﬁnal interpretation was made by consensus. Based on pre-
vious descriptions of HRCTs in HSCT recipients [18], the presence of the
following radiological parameters was established: bronchiectasis, bron-
chial wall thickening, air trapping (or mosaic pattern if no expiratory scan
was available), consolidation, ground glass opacities, and centrilobular
opacities.
PF Tests
PF tests followed the recommendations from the European Respiratory
Society and American Thoracic Society [19-21] using the ScreenPro and
MasterLab (Jaeger, Hoechberg, Germany). Diffusion capacity of the lungs for
carbon monoxide (DLCO) and total lung capacity were measured by thesingle-breath helium dilution technique. DLCO was corrected for hemoglobin
value. The results are presented as percent of predicted value, based on age-
matched reference materials for spirometry [22], DLCO [23,24], and static
lung volumes [21,23].
For longitudinal analysis, PF tests were sorted into time intervals relative
to the time of lung biopsy: within 3 months before lung biopsy, 3 to 9
months, 9 to 18 months, and last available measurement beyond 18 months
from the lung biopsy. When more than 1 measurement was available per
patient per time interval, the median value was chosen.
Residual volume, which is needed for a full BOS classiﬁcation according
to the NIH criteria [2], was available in only a few patients. We therefore
applied a previously published modiﬁed version of the NIH criteria to
establish the BOS diagnosis: FEV1 < 75% of predicted normal and FEV1/FVC
ratio < .7 and a decrease in FEV1 by 10% compared with pretransplant
values [4].Statistics
Associations were tested using the Fisher exact test and Wilcoxon rank
sum test. Longitudinal differences and changes in PF between BO and non-
BO patients from time of biopsy were estimated in a linear mixed model
with repeated measures. Non-normally distributed data were log trans-
formed for analysis. To detect bias due to different biopsy techniques, results
were validated in subset analyses that only included patients diagnosed
with open lung biopsy.
To compare the value of lung biopsy and BOS criteria in predicting long-
term decline in PF, a decrease in FEV1 of more than 20% from (pre-HSCT)
baseline to 18 months postbiopsy was deﬁned as the outcome parameter.
Based on the deﬁnition of BOS in lung transplant recipients [25,26], a 20%
decrease in FEV1 from baseline was chosen as primary endpoint for a clin-
ically signiﬁcant decrease in PF. As a second endpoint, we compared the
associations between BO and BOS diagnoses and death at 18 months post-
biopsy. The 18-month threshold was based on the fact that this time point
was reached by all participants at the time of this study. Associations were
tested in logistic regression models.
For survival analyses, the BO and non-BO patients in our cohort were
compared with the background population of Danish HSCT recipients
transplanted in Denmark between 2000 and 2010 who survived beyond 3
months from HSCT (n ¼ 698). Survival rates were calculated from time of
HSCT and time of lung biopsy. Overall survival probabilities were plotted in
Kaplan-Meier curves. Estimates were compared with Cox proportional
hazard models. Differences in relapse rates and treatment-related mortality
were analyzed using competing risks methodology. Statistical analyses were
performed in SPSS Statistics (version 19, IBM, Armonk, NY) and SAS (version
9.2; SAS Institute, Cary NC). P < .05 were considered to be signiﬁcant.RESULTS
Of the 742 patients who underwent HSCT in Denmark
between 2000 and 2010 and survived beyond 3 months, 59
patients had an open or a transbronchial lung biopsy per-
formed on suspicion of BO (Figure 1). Forty-four patients
were diagnosed with noninfectious pulmonary pathology
and were included in this study. Of these, 23 patients had BO
and 21 patients presented noninfectious lung pathology
other than BO, including COP (n¼ 6), diffuse alveolar damage
(n¼ 3), unspeciﬁc interstitial ﬁbrosis (n¼ 11), and interstitial
pneumonia (n ¼ 1). Characteristics of the study population
are presented in Table 1. In 5 patients, BO was diagnosed in a
second biopsy. In these patients, the ﬁrst biopsy had shown
bronchopneumonia (n ¼ 1), COP (n ¼ 1), diffuse alveolar
damage (n ¼ 1), or unspeciﬁc inﬂammation (n ¼ 2).
Ninety-one percent of BO cases (21/23) and 62% of non-
BO cases (13/21) (P ¼ .031) were diagnosed by open lung
biopsy. The remaining cases were diagnosed with trans-
bronchial biopsies. The most common biopsy-related
morbidity included pain and a transient increase in the
requirement for O2 support. Minor pneumothorax was seen
on x-ray after both open (8/34, 23.5%) and transbronchial
biopsies (2/10, 20.0%). In 1 patient who received a trans-
bronchial biopsy, pneumothorax required transthoracic
drainage. In 3 patients who received open lung biopsies (3/
34, 8.8%) the pneumothorax was combined with the devel-
opment of subcutaneous emphysema. Infections related to
Figure 1. Study population. TBB indicates transbronchial biopsy.
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patient developed a minor bleeding (1/34, 2.9%) after open
lung biopsy. Three patients died during the hospital stay at
which the biopsy was performed. Causes of death were
bacterial pneumonia, interstitial pneumonia, and BO,
respectively.HRCT and Clinical Characteristics at Time of Lung Biopsy
The decision to perform a lung biopsy was based on
clinical symptoms (cough, dyspnea, increased oxygen need),
reduced PF, and/or pathological ﬁndings on HRCT (especially
air trapping, bronchiectasis, and peribronchial thickening),
combined with an individualized risk assessment of this
invasive procedure. The decision was made by transplant
physicians in collaboration with thoracic surgeons but
without speciﬁc radiological or clinical cut-off-points to
guide the decision.
Cough and dyspnea were present in most patients, both
BO and non-BO, before lung biopsy. A larger proportion of
the non-BO patients were in need of O2 supplement
(Table 2). PF tests performed a median of 7 days (range, 1 to
90) before the lung biopsy showed a signiﬁcantly larger
decrease in the FEV1/FVC ratio compared with pre-HSCT
values in patients who were later diagnosed with BO
compared with patients with other pulmonary pathologies
(Table 3, Figure 2).
HRCT was performed in 77.2% of patients (34/44), of
whom 82.3% (28/34) presented ﬁndings that led to a suspi-
cion of BO (air trapping/mosaic pattern, bronchiectasis, per-
ibronchial thickening), whereas infectious pathology
(consolidation, ground glass opacities) was suspected in
35.3% of patients (12/34).We found no signiﬁcant differences
in the presentation of air trapping, peribronchial thickening,and bronchiectasis in HRCTs performed in patients with BO
compared with non-BO pathologies (Table 2).
The accordance between pathological BO diagnosis and
the modiﬁed BOS criteria is described in Table 4. The sensi-
tivity of the modiﬁed BOS criteria for biopsy-veriﬁed BO was
52.4% and the speciﬁcity 76.5%. The positive predictive value
was .73 and the negative predictive value .57. When only
patients diagnosed by open lung biopsy (as opposed to
transbronchial biopsy) were included, the sensitivity and
speciﬁcity were 57.9% and 63.6%, respectively.Treatment
In most patients, prednisolone in combination with
other immunosuppressive drugs was used as ﬁrst-line ther-
apy after biopsy-based diagnosis (Table 5). There was a
tendency toward a higher intensity of treatment in the BO
group, because a larger proportion of these patients received
a combination of 3 or more immunosuppressive drugs once
the diagnosis had been established (9/23 versus 1/21,
P ¼ .048).Long-Term Lung Function Follow-up
The last available PF tests were performed at a median of
47 months (range, 18 to 112) for BO patients and of 44
months (range, 18 to 122) for non-BO patients after the lung
biopsy. From time of biopsy and throughout follow-up, BO
patients exhibited lower values of FEV1, FEV1/FVC, maximal
mid-expiratory ﬂow (MMEF), FVC, and DLCO compared with
non-BO patients. However, no signiﬁcant differences be-
tween the 2 groups in the change in PF parameters during
follow-up were found (Figure 2). The results were validated
in subanalyses only including patients diagnosed by open
lung biopsy (34/44). In this analysis we also found
Table 2
Clinical Characteristics at Time of Lung Biopsy for BO and Non-BO Patients
BO Non-BO P Value of
Difference
Months from HSCT to
lung biopsy, median
(range)
13.7 (3.3-44.6) 10.0 (2.8-83.4) .41
Respiratory symptoms,
n (%)
Cough 22 (95.7) 20 (95.2) 1.0
Dyspnea 20 (86.9) 21 (100.0) .23
Fever 3 (13.0) 5 (23.8) .43
Hypoxia 3 (13.0) 10 (47.6) .020
Lung function values,
mean (SD)
FEV1 % predicted 46.7 (14.0) 63.8 (28.8) .054
FVC % predicted 57.4 (14.6) 63.4 (25.9) .61
FEV1/FVC % predicted 82.4 (20.1) 101.2 (18.0) .002
MMEF % predicted 33.7 (25.9) 105.2 (60.4) .001
TLC % predicted 70.8 (11.8) 71.3 (19.5) .85
DLCO % predicted 52.3 (14.1) 45.1 (23.2) .16
HRCT ﬁndings, n (%)*
Air trapping or mosaic
pattern
11 (55.0) 11 (78.6) .28
Bronchiectasis 17 (85.0) 12 (85.7) 1.0
Peribronchial
thickening
17 (85.0) 12 (85.7) 1.0
Consolidation 13 (65.0) 11 (78.6) .47
Ground glass opacities 13 (65.0) 11 (78.6) .47
Centrilobular opacities 14 (70.0) 5 (35.7) .080
cGVHD in other organ
system, n (%)y
13 (56.5) 7 (33.3) .14
Skin 3 (13.0) 2 (9.5)
Mouth 13 (56.5) 6 (28.6)
Eyes 7 (30.4) 4 (19.0)
Other 1 (4.3) 0
Immunosuppressive
therapy, n (%)
19 (82.6) 13 (61.9) .18
Cyclosporine 11 (47.8) 5 (23.8)
Tacrolimus 1 (4.3) 3 (14.3)
Prednisolone 12 (52.2) 6 (28.6)
Mycophenolate mofetil 10 (43.5) 4 (19.0)
Rapamune 3 (13.0) d
TLC indicates total lung capacity.
* Percentage values calculated based on the number of patients with
available scans.
y Only changes classiﬁed as diagnostic or distinctive of cGVHD according to
the NIH consensus criteria [2] are included.
Table 1
Characteristics of the Study Population (N ¼ 44)
BO (n ¼ 23) Non-BO
(n ¼ 21)
P Value of
Difference
Median recipient
age, yr (range)
40.7 (.6-61.8) 49.7 (.7-59.4) .43
Diagnosis malignant 19 (82.6) 18 (85.7) 1.0
AML 4 (17.4) 3 (14.3)
ALL 4 (17.4) 6 (28.6)
CML 3 (13.0) 2 (9.5)
Lymphoma 3 (13.0) d
Other malignancies 5 (21.7) 7 (33.3)
Nonmalignant
hematological diseases
3 (13.0) 2 (9.5)
Other diseases 1 (4.3) 1 (4.7)
HLA-identical sibling
donor
11 (47.8) 10 (47.6) .47
Matched unrelated donor
(10/10 or 9/10 match)
7 (30.4) 9 (42.9)
Unrelated donor
(>1 allele mismatch)
5 (21.7) 2 (9.5)
Median donor age,
yr (range)
38.3 (15.4-57.8) 37.3 (20.0-69.0) .80
Sex mismatch
Male to female 4 (17.4) 2 (9.5) .67
Female to male 6 (26.1) 12 (57.1) .065
CMV mismatch
Positive donor to
negative recipient
3 (13.0) 5 (23.8) .45
Negative donor to
positive recipient
6 (26.1) 3 (14.3) .46
Stem cell source
Bone marrow 8 (34.8) 7 (33.3)
Peripheral blood 15 (65.2) 14 (66.7) 1.0
Umbilical cord d d 1.0
Median cell dose/kg
(range)
7.8 (2.4-27.8) 5.9 (.3-12.7) .11
Chemotherapy
BU 9 (39.1) 7 (33.3) .76
TBI 14 (60.9) 13 (61.9) .75
CY 13 (56.5) 13 (61.9) .77
Etoposide 3 (13.0) 3 (14.3) 1.0
FLU 7 (30.4) 5 (23.8) .74
Conditioning regimen
BUþCY 9 (39.1) 7 (33.3) .76
TBIþCY 4 (17.4) 5 (26.3) .71
TBIþetoposide 3 (13.0) 3 (14.3) 1.0
TBIþFLU 7 (30.4) 5 (23.8) .74
Other d 1 (4.8) d
Acute GVHD occur 13 (56.5) 9 (42.9) .55
Grade I 4 (17.4) 3 (14.3)
Grade II 8 (34.8) 5 (23.8)
Grade III 1 (4.3) 1 (4.8)
Grade IV d d
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia;
CML, chronic myelogenous leukemia; CMV, cytomegalovirus; BU, busulfan;
TBI, total body irradiation; CY, cyclophosphamide; FLU, ﬂudarabine.
Values are number of case with percents in parentheses, unless otherwise
indicated.
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.0001), MMEF (P¼ .0003), and DLCO (P¼ .012) in the group of
BO patients, but there was no difference between BO and
non-BO patients in the change in PF during follow-up from
time of biopsy.
In a bivariate logistic regression model, we compared the
association between a 20% decrease in FEV1 from pre-HSCT
to 18 months postbiopsy and the diagnoses of biopsy-based
BO and clinically deﬁned BOS, respectively. The odds ratio
(95% conﬁdence interval) for the association with a 20%
decrease in FEV1 was 3.1 (.6 to 15.5, P ¼ .16) for patients with
biopsy-veriﬁed BO and 3.1 (.6 to 16.5, P ¼ .18) for patients
with BOS. Neither BO nor BOS were signiﬁcantly associated
with death at 18 months postbiopsy (odds ratio, 1.6 [95% CI,.3 to 9.2], P ¼ .58), and odds ratio, 1.6 (95% CI, .2 to 10.1], P ¼
.64, respectively).
Survival
BO patients and non-BO patients had similar overall sur-
vival rates (Figure 3). Likewise, both groups had similar
survival rates as the background population of HSCT re-
cipients. There was no difference in treatment-related mor-
tality: cumulated incidence at 3 years from HSCT was .13
(95% CI, .03 to .30) for BO patients, .095 (95% CI, .015 to .27)
for non-BO patients, and .14 (95% CI, .13 to .17) for the
background population (P¼ .77). The cumulated incidence of
relapse mortality for BO patients was .048 (95% CI, .003 to
.202), for non-BO patients .26 (95% CI, .06 to .41), and for the
background population .25 (95% CI, .22 to .29) (P ¼ .18).
Survival analysis with the date of lung biopsy as the starting
point did not show any difference in overall survival between
BO and non-BO patients (Figure 3).
DISCUSSION
This is to date the largest study of BO in a cohort of HSCT
patients deﬁned clinically by pulmonary manifestations
leading to lung biopsy. Compared with HSCT patients with
Table 3
Decrease in PF from Pre-HSCT Baseline to Time of Biopsy in BO and Non-BO Patients
BO Non-BO P Value of Difference
Between BO and Non-BO
Patients
Mean Decrease (SD)
from Baseline to Time
of Biopsy
95% CI of
Difference
Mean Decrease (SD)
from Baseline to Time
of Biopsy
95% CI of
Difference
FEV1 % predicted 39.7 (18.5) 31.3-48.1 33.9 (23.5) 21.8-46.0 .40
FEV1/FVC % predicted 17.2 (18.0) 9.0-25.4 2.7 (15.7) 5.4-10.8 .013
MMEF % predicted 50.8 (34.7) 30.7-70.8 25.3 (38.6) 4.4-54.9 .050
FVC % predicted 29.0 (16.9) 21.3-36.7 29.5 (22.8) 17.7-41.2 .94
TLC % predicted 23.6 (12.7) 16.9-30.4 25.5 (19.1) 10.8-40.2 .77
DLCO % predicted 21.2 (17.3) 10.2-32.2 30.3 (28.9) 13.6-47.0 .35
Figure 2. Development of lung function in patients with biopsy-veriﬁed BO compared with patients with other noninfectious pulmonary pathologies (non-BO). *P
value relates to the difference between BO and non-BO patients in PF parameters from time of lung biopsy and throughout follow-up. **P value relates to the dif-
ference between BO and non-BO patients in change in PF parameters from time of lung biopsy.
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Table 4
Fulﬁllment of Modiﬁed NIH Criteria for BOS at Time of Biopsy
BO Non-BO P
FEV1 < 75% of predicted value 21 (100) 13 (76.5) .032
FEV1/FVC ratio < .7 11 (52.4) 4 (23.5) .10
>10% decrease in FEV1 from baseline 19 (90.5) 14 (82.4) .64
Modiﬁed NIH criteria fulﬁlled 11 (52.4) 4 (23.5) .10
Values in parentheses are percentages calculated based on number of pa-
tients with available measurements.
Figure 3. (A) Overall survival in time from HSCT in patients with biopsy-
veriﬁed BO compared with patients with other noninfectious pulmonary pa-
thology (non-BO) and HSCT patients without lung biopsy from the same
period. 1P value of difference between the 3 groups. (B) Overall survival in time
from lung biopsy.
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BO exhibited signiﬁcantly reduced PF parameters from time
of lung biopsy and throughout follow-up. The BO diagnosis
was not associated with reduced survival.
The NIH BOS criteria were originally established to pro-
vide a noninvasive tool for BO diagnosis. The sensitivity and
speciﬁcity of the BOS criteria for pathological BO in our study
were relatively low, because only half the patients with BO
and 24% of the patients with other noninfectious pulmonary
pathologies met a modiﬁed version of the BOS criteria. This
corresponds to the report from Holbro et al. [27] where 7 of
14 patients with biopsy-veriﬁed BO and 3 of 10 with other
pathology (lymphocytic bronchiolitis) fulﬁlled the BOS
criteria. The HRCT patterns of air trapping, bronchiectasis,
and peribronchial thickening, included in the original NIH
BOS criteria, were present in up to 86% of the patients in our
cohort but had low speciﬁcity for the biopsy-veriﬁed BO
diagnosis. Accordingly, bronchiectasis and bronchial wall
thickening have been reported in restrictive [28] and in
obstructive [18,29] HSCT-related lung diseases but appear
not to be speciﬁc to BO or BOS. Air trapping, which has been a
reported almost universal ﬁnding in HSCT patients with
airﬂow obstruction [18,29,30], may have been under-
estimated in our cohort, because only half the patients had
available expiratory images.
Lung biopsy has the potential advantage of discriminating
between infectious and noninfectious pulmonary pathol-
ogies that may require different treatment strategies. How-
ever, in this cohort of patients with noninfectious
pathologies, we did not ﬁnd the pathological BO diagnosis toTable 5
First-Line Therapy for Pulmonary Complications after Lung Biopsy
Drugs Used BO Non-BO* P
High-dose methylprednisolone 8 (34.8) 8 (38.1) 1.0
Oral prednisolone 19 (82.6) 17 (81.0) 1.0
Cyclosporine 13 (56.5) 8 (38.1) .25
Mycophenolate mofetil 12 (52.2) 3 (14.3) .011
Tacrolimus 2 (8.7) 2 (9.5) 1.0
Rapamune 3 (13.0) 0 .23
Inﬂiximab 1 (4.3) d d
Rituximab 1 (4.3) d d
Initial drug combinations
Prednisolone alone 2 (8.7) 7 (33.3) .064
Cyclosporine alone 2 (8.7) d d
Mycophenolate mofetil alone 1 (4.3) d d
PredþCy 4 (17.4) 6 (28.6) .48
PredþMPM 2 (8.7) 2 (9.5) 1.0
Predþother 3 (13.0) 3 (14.3) 1.0
PredþCyþMPM 5 (21.7) 1 (4.8) .19
PredþCyþother 2 (8.7) d d
PredþMPMþother 2 (8.7) d d
Pred indicates prednisolone; Cy, cyclosporine; MPM, mycophenolate
mofetil.
Values in parentheses are percentages of the total number of patients.
* Two non-BO patients did not receive any immunosuppressive therapy
after lung biopsy.be a better predictor of long-term pulmonary impairment
than the BOS criteria that were based on PF tests alone. The
biopsy discriminated BO patients from non-BO patients, who
exhibited signiﬁcantly higher values of FEV1, FEV1/FVC, and
MMEF from time of lung biopsy and during follow-up.
However, the change in PF beyond the time of biopsy did
not differ signiﬁcantly between BO and non-BO patients. In
contrast, Holbro et al. [27] found that although BO patients
exhibited no signiﬁcant increment in FEV1, patients with
other noninfectious pulmonary pathology (lymphocytic
bronchiolitis) exhibited a signiﬁcant and sustained
improvement from 6 months postbiopsy. Based on these
retrospective studies, we cannot reach a ﬁnal conclusion on
the role of lung biopsy in the diagnosis of post-HSCT pul-
monary complications, but our study underlines the value of
spirometry as a valid predictive parameter of long-term
pulmonary morbidity.Survival
Three previous studies have described the course of
biopsy-veriﬁed BO in HSCT patients. In 2 minor studies of
HSCTs conducted between 1976 and 1985, patients with BO
had severely reduced pulmonary capacity, and 70%-100% of
these patients died [31,32]. Holbro et al. [27] described HSCT
patients transplanted between 1989 and 2010 and found that
50% (7/14) of the BO patients died. Overall survival was
signiﬁcantly reduced in patients with BO compared with
patients with other pulmonary pathology (lymphocytic
bronchiolitis) [27]. In our cohort, BO diagnosis was not
associated with reduced survival compared with non-BO
patients or with HSCT recipients not having a lung biopsy.
Although the time of follow-up after lung biopsy was similar
in our study and Holbro’s study [27], the criteria for per-
forming a lung biopsy might differ between the centers.
Although the number of cases in the current study is too
small to draw deﬁnite conclusions, changes in transplant
H.H. Uhlving et al. / Biol Blood Marrow Transplant 21 (2015) 531e538 537protocols and improved therapy over the past decades may
explain the better survival of the BO patients observed in our
cohort.Pathogenesis
The pathogenesis of BO is not fully understood, and it is
conceivable that some of the other noninfectious pulmonary
pathologies may represent early stages of BO. Based on
pathological studies, Yousem [33] hypothesized that lym-
phocytic bronchiolitis, diffuse alveolar damage, COP, and BO
represented different stages of GVHD-related lung disease. In
support of this hypothesis, 4 of our patients with BO had
previous biopsies showing diffuse alveolar damage, COP, and
unspeciﬁc inﬂammation. Accordingly, several case studies of
patients with autopsy-veriﬁed BO found COP, lymphocytic
bronchiolitis, and interstitial pneumonia in lung biopsies
performed when the patients were still alive [34-36]. In a
study of serial lung biopsies in lung transplant recipients,
COP and interstitial pneumonia in the early post-transplant
period were associated with the later occurrence of BO
[37]. Because of the pathological and clinical similarities [38],
it is conceivable that similar relations exist between patho-
logical patterns encountered in HSCT recipients as well.
Whether it is possible to inhibit the pathological processes
leading to BO by increased immunosuppressive therapy at an
earlier stage is a topic for further research, where lung bi-
opsies, when performed in a protocolled manner, may
improve our insights into the pathophysiology of these
complications.
A major strength of this study is the availability of
detailed clinical data in all patients. The patients were
transplanted over a 10-year period during which the main
elements of the protocol and supportive therapywere largely
unchanged. Still, the study has weaknesses. The performance
of lung biopsymay have been avoided in themost severely ill
patients, resulting in bias in the study population. Because a
higher proportion of BO compared with non-BO patients
were diagnosed by open lung biopsy, which is assumed to
have higher sensitivity than transbronchial biopsy [39], some
cases of BO may have been misclassiﬁed. The validity of our
results, however, was conﬁrmed in subset analyses, where
only patients with open lung biopsy were included.
The HRCT scanning protocols and image quality have
changed during the study period, which make systematic
evaluation and comparison difﬁcult. Our evaluation may not
have had a sufﬁcient level of accuracy to distinguish differ-
ences between BO and non-BO, but imaging per se may not
be sensitive enough to detect these differences anyway.
Prospective studies with uniform scanning protocols and
validated scoring systems are warranted to evaluate the
applicability of HRCT in BO and BOS diagnosis. Furthermore,
new techniques to improve sensibility and the quantiﬁcation
of small airways disease on HRCT, such as spirometric vol-
ume control [40] and quantitative biomarkers such as para-
metric response mapping [41], might prove valuable in the
diagnosis of BO.
The BOS criteria applied in the current study were from a
previously published, modiﬁed version of the NIH criteria [4]
with the advantage only to rely on spirometry, which is
available at most centers. However, several modiﬁcations of
the NIH BOS criteria have been applied in different studies
[4,5,7,8,15,17,18,42-47], which makes comparison difﬁcult
and indicates a need for a more simple and widely accepted
classiﬁcation.In conclusion, patients with biopsy-veriﬁed BO had
signiﬁcantly lower values of PF than non-BO patients from
time of biopsy and throughout follow-up, but the change in
PF did not differ signiﬁcantly between the groups. Although
the BOS criteria had low sensitivity and speciﬁcity for path-
ological BO, the pathological BO diagnosis was not superior
to the BOS criteria in the prediction of long-term decrease in
PF. Accordingly, the BOS criteria, or the assessment of PF as
such, may provide important noninvasive alternatives to
lung biopsy for the prediction of long-term pulmonary
morbidity. However, the BOS criteria do not allow distinction
between infectious and noninfectious pathologies, which
could inﬂuence the treatment strategy of individual patients,
and do not provide information about the etiology of the
pulmonary disease. Future, prospective studies should focus
on strategies for early detection of noninfectious pulmonary
complications to investigate whether the pathological pro-
cess leading to BO can be reversed by increased immuno-
suppressive therapy at an earlier stage.ACKNOWLEDGMENTS
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